Therapeutic drug monitoring of imatinib--new data strengthen the case.
A population pharmacokinetic study of imatinib in patients with gastrointestinal stromal tumor by Eechoute and colleagues has shown a significant increase in drug clearance over the first 3 months of treatment, resulting in a 30% decrease in drug exposure. This finding clearly shows the possibility of pharmacokinetic resistance in this disease.
Sarcoma Unit, Royal Marsden Hospital, Fulham Road, London, United Kingdom. Ian.Judson@icr.ac.uk
Ian
I
Judson
D000970:Antineoplastic Agents; D001549:Benzamides; D005260:Female; D046152:Gastrointestinal Stromal Tumors; D006801:Humans; D000068877:Imatinib Mesylate; D008113:Liver Neoplasms; D008297:Male; D010879:Piperazines; D011743:Pyrimidines
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate